Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

High rates of virologic suppression were observed among Black patients who received long-term ART with BIC/FTC/TAF for HIV management.

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...